Isomer abundance of bis(beta-diketonato) complexes of titanium(IV). Crystal structures of the antitumor compound budotitane [Ti(IV)(bzac)(2)(OEt)(2)] and of its dichloro-derivative [Ti(IV)(bzac)(2)Cl(2)] (bzac=1-phenylbutane-1,3-dionate).

The molecular tumor inhibiting titanium compound budotitane [Ti(IV)(bzac)(2)(OEt)(2)] (1) and its dichloro-derivative [Ti(IV)(bzac)(2)Cl(2)] (2) (bzac=1-phenylbutane-1,3-dionate) have been crystallized and characterized by X-ray crystallography and further physical methods. Budotitane (1) crystallizes in the tetragonal, non-centrosymmetric space group P4(1) with two molecules in the asymmetric unit. Both molecules adopt the cis-cis-trans configuration with the acetyl ends of the benzoylacetonate ligands in the trans position.

The interaction of 5-fluoroorotic acid with transition metals: synthesis and characterisation of Ni(II), Cu(II) and Zn(II) complexes.

5-Fluoroorotic acid (H(3)FOro) is a potent inhibitor for some metalloproteins such as dihydroorotase and dihydroorotate dehydrogenase and for thymidylate synthase (nonmetalloprotein) in the human malaria parasite Plasmodium falciparum. To study the coordination chemistry of H(3)Foro, the ammonium salt [NH(4)(+)][H(2)FOro(-)].1H(2)O (1) and the first coordination compounds of H(3)FOro with transition metals [Ni(HFOro(2-))(H(2)O)(4)].

Platinum complexes of oxopurines: cis-bis(theophyllinato-N7)bis(triphenylphosphine)platinum(II) and cis-chloro(theobrominato-N1)bis(triphenylphosphine)platinum(II) ethanol hemisolvate.

The syntheses and structures of two mixed-ligand complexes of platinum(II) with deprotonated oxopurine bases and triphenylphosphine are reported, namely the theophyllinate complex cis-bis(1,2,3,6-tetrahydro-1,3-dimethylpurine-2,6-dionato-kappaN(7))bis(triphenylphosphine-kappaP)platinum(II), [Pt(C(7)H(7)N(4)O(2))(2)(C(18)H(15)P)(2)], (I), and the theobrominate complex cis-chloro(1,2,3,6-tetrahydro-3,7-dimethylpurine-2,6-dionato-kappaN(1))bis(triphenylphosphine-kappaP)platinum(II) ethanol hemisolvate, [PtCl(C(7)H(7)N(4)O(2))(C(18)H(15)P)(2)].0.5C(2)H(5)OH, (II).

Synthesis and Characterization of an Octanuclear Mixed-Ligand Copper(II) Complex of the Immunosuppressant Thiopurine Drug Azathioprine.

An octanuclear mixed-ligand copper(II) complex of the immunosuppressant drug azathioprine (AZA) and 2,2,6,6-tetramethylheptane-3,5-dione (THD), [{Cu(4)(AZA(-))(2)(THD(-))(5)(OH(-))}(2)].2CH(3)CN, has been synthesized and characterized by X-ray crystallography and by mass spectrometric and magnetic measurements. Eight copper(II) ions, four monodeprotonated azathioprine(-) ligands, ten monodeprotonated THD(-) ligands, and two hydroxide anions are assembled to form a centrosymmetric, octanuclear molecule, where two tetranuclear moieties of the molecule are connected by four coordination bonds between copper atoms and the N(3) and N(9) atoms of two different AZA ligands.

A mixed-valence iron complex of the antitumour drug 6-mercaptopurine: tris(6-mercaptopurine)iron(II) tetrachloroferrate(III) chloride.

Single crystals of the title complex, tris(1, 6-dihydro-9H-purine-6-thione-N(7),S)iron(II) tetrachloroferrate(III) chloride, [Fe(C(5)H(4)N(4)S)(3)][FeCl(4)]Cl, were grown on the surface of solid 6-mercaptopurine monohydrate pellets in a solution of iron(III) chloride. The solution of the hexagonal structure required the application of twin refinement techniques. All the component ions lie on threefold rotation axes.